Bioventus (BVS) had its price target raised by Barrington Research from $13.00 to $14.00. They now have an "outperform" rating on the stock.
Bioventus (BVS) had its price target raised by Craig Hallum from $15.00 to $16.00. They now have a "buy" rating on the stock.
Bioventus Q4 Earnings Call Highlights [Yahoo! Finance]
Bioventus outlines $600M–$610M 2026 sales target with accelerated investment in PNS, PRP, and ultrasonics [Seeking Alpha]
Bioventus Inc. (BVS) Q4 2025 Earnings Call Transcript [Seeking Alpha]